Claim construction issues in ANDA case

Shire LLC, et al. v. Teva Pharmaceuticals USA, et al., Civil Action No. 10-329 RGA, March 22, 2012.

Andrews, J.  The court rules on seven disputed terms after Markman hearing.

The three patents-in-suit relate to Intuniv®, a drug used to treat pediatric ADHD. The terms considered include:

Without inducing excessive sedation

Readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition

Non-pH dependent sustained release agent

pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5
polymer that swells at a pH in excess of 5.5

Agent that increases the solubility of said at least one pharmaceutically active agent at a pH of greater than 5.5

Agent that maintains an acidic microenvironment in the composition

Reducing the likelihood of side effects associated with the administration of guanfacine
 

Trackbacks (0) Links to blogs that reference this article Trackback URL
http://depatentlaw.morrisjames.com/admin/trackback/274274
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?
Send To A Friend Use this form to send this entry to a friend via email.